Why Invest in a Gynaecology PCD Pharma Franchise: Opportunities and Challenges

 The Indian pharma market is estimated to reach a phenomenal $130 billion by 2030 with speciality areas like gynaecology inducted with huge growth. According to the forecast, the gynaecology drug market in India is going to grow at 8.3% CAGR during 2022-2027, at least by 2024. Increased focus on women's reproductive health, higher awareness of diseases affecting women, and government focus on healthcare programs for women are considered the drivers for the growth of this market.

Along with these, increasing infertility problems, hormonal disorders, health issues related to women's menstrual cycles, and health issues of mothers have augmented the demand for gynaecological products. According to reports, about 15% of Indian couples suffer from problems of infertility; hence, there is a high requirement for gynaecological products such as fertility medicines and hormonal drugs. To cater to these requirements Gynofert offers its Gynae PCD Pharma Franchise in India. Let’s discuss the opportunities and challenges faced in a Gynaecology PCD Pharma Franchise.

Growing Demand for Gynae Products

The gynaecology segment is very broad and ranges from contraceptives to hormone replacement therapy, all the way to PCOS drugs, menstrual health drugs, and fertility treatments. India alone houses a staggering population of 400 million women of reproductive age, which makes the country a massive market for drugs regarding gynaecology care. Another reason is the rising prevalence of diseases, including ovarian cancer and endometriosis, for which gynaecology drugs are very much needed.

About 20% of women in India are suffering from some menstrual disorders in 2024; around 10 million women are suffering from PCOS. This is making a separate specific gynaecology drug market, and thus, this can be one of the most suitable pharmaceutical investment fields.

Gynaecology PCD Pharma Franchise Opportunities

There are various reasons why a gynaecology PCD pharma franchise is an excellent investment opportunity. There will always be a demand for products used in women's healthcare, including hormonal therapies, pregnancy supplements, and fertility drugs. The high trend is predominant in reproductive health, especially in rural and semi-urban regions, which hold a yet untouched market for gynaecological treatments. The gynaecology drug market is likely to grow at a CAGR of 8.3% through the period of 2022-2027 and will thus be a beneficial investment based on expanding product portfolio and continuous demand for essential medicines.

Another benefit of the gynaecology PCD franchise sector is its very high profitability. Since gynaecological treatment has the capability to save patients' lives, patients are rather inelastic to prices and an efficient demand and supply chain yields good returns on investment. Moreover, there are various products ranging from hormonal treatments to supplements for pregnant women, which sustain constant inflows of revenue and ensure long-term sustainability.

Challenges Faced in Gynaecology PCD Pharma Franchise

However, the industry is not free of problems. Gynaecology drugs have very strict rules and regulations that need stringent execution. Proper documentation of all products and quality control must be maintained for legal compliance. Branding is also very challenging because the PCD franchisee needs to have an efficient marketing strategy to establish a brand. Most of all, inventory management and the efficacy of the supply chain are crucial, especially in products where the shelf life is short. Besides that, educating the physician community is also important, especially by informing them about novel treatments that can be administered in the periphery.

The gynaecology drug market is expected to grow to the level of ₹ 20,000 crores by 2024, driven by increasing demand both in urban and rural India.